Which is better for the liver, TUDCA or NAC?

NAC on the score, 8.0 against 6.5 on liver detox, but the two treat different liver problems. NAC's evidence is toxic and oxidative injury, anchored by Smilkstein 1988 in 2,540 acetaminophen-overdose patients. TUDCA's is cholestatic, anchored by a cirrhosis RCT (Pan 2013) and a primary biliary cirrhosis crossover (Larghi 1997). Pick by which problem you have.

Should I take TUDCA if my bile is sluggish?

Yes, this is TUDCA's actual job. It modulates the bile acid pool and bile flow through the farnesoid X receptor and bile salt export pump, which is why its gut-health subrating is 5.8 against NAC's 3.0. Rule out complete biliary obstruction with a clinician first, and get clearance if you are already on UDCA, cholestyramine or another liver medication.

Is NAC worth taking if I have no liver problem?

Often yes, for reasons that are not about the liver. Its antioxidant subrating is 7.5, its respiratory 7.5 and its mood 6.0, and it costs $5 to $15 a month. Do not expect to feel it. For a healthy person it is quiet biochemical support rather than something you notice, which is a fair thing to buy at that price.

Can I take TUDCA and NAC together?

Mechanistically nothing conflicts. NAC works through cysteine, glutathione and the cystine-glutamate antiporter; TUDCA through ER-stress chaperoning, the farnesoid X receptor and bile flow. No trial in either report tested the combination, so run them as two separate experiments and add one at a time against a marker you chose in advance.

Does TUDCA protect nerves or help ALS?

The evidence went the wrong way. The excitement came from AMX0035, which combined taurursodiol with sodium phenylbutyrate, and the 664-participant PHOENIX Phase 3 trial missed its endpoints in 2024 with the product withdrawn from market. Elia 2016 was a small positive add-on trial that was never replicated. Do not buy TUDCA for this.

How long before either one works?

Both carry a 12-week assessment window. NAC's first noticeable change is around 2 weeks with its report putting full effect out at 12 months. TUDCA shows first change at about 4 weeks with full effect at 12. Pick a marker before you start, whether that is ALT, exacerbation count or how you handle a fatty meal, and judge at 12 weeks.

How much NAC should I take?

600 to 1,200 mg a day for general antioxidant and glutathione support. If the target is COPD or chronic bronchitis, take 600 mg twice daily rather than once: PANTHEON used the twice-daily dose and cut exacerbations 22%, while BRONCUS at 600 mg once daily was null. Dose is the difference between those two results.

Is NAC safe to take every day?

For most people yes, with a specific list to check first. Its contraindications are nitrates because of additive hypotension, active peptic ulcer disease, anticoagulant or antiplatelet therapy because of bleeding-time effects, known cysteine hypersensitivity, and reactive airway disease for the inhaled mucolytic form only. Pregnancy and lactation need medical supervision.

Head-to-Head Comparison

TUDCA vs NAC: Which Is Better for Your Liver?

Should I take TUDCA or NAC for my liver?

Reviewed 09/08/2026

Different liver problems. NAC scores 8.0 and TUDCA 6.7, and NAC wins liver detox 8.0 against 6.5, but its liver evidence is toxin and oxidative damage. TUDCA owns bile flow, cholestasis and gut. If your issue is sluggish bile or fat digestion, the lower-scoring one is correct. Otherwise start with NAC.

NAC 8.0, TUDCA 6.7. NAC is broader, cheaper and better evidenced almost everywhere.
Liver detox goes to NAC 8.0 against 6.5, but read what each one's liver evidence is actually about before using that row.
NAC's liver record is poisoning: Smilkstein 1988 in 2,540 patients cut hepatotoxicity to 6.1% when started within 10 hours.
TUDCA's liver record is bile: a double-blind cirrhosis RCT (Pan 2013) and a primary biliary cirrhosis crossover (Larghi 1997).
TUDCA wins gut 5.8 against 3.0, blood sugar 5.5 against 3.0 and metabolic health 5.5 against 4.0. Kars 2010 found roughly 30% better hepatic and muscle insulin sensitivity in four weeks.
NAC wins antioxidant 7.5 against 1.5, respiratory 7.5 against 1.5, substance use 6.5 against 1.5 and mood 6.0 against 1.5.
Cost is not close: $5 to $15 a month for NAC, extracted from the report, against $12 to $91 for TUDCA at 500 to 1,750 mg.
Do not buy TUDCA for nerves. AMX0035 combined taurursodiol with sodium phenylbutyrate and the PHOENIX Phase 3 trial failed in 2024.

At a Glance

Option A

TUDCA (Tauroursodeoxycholic Acid)

6.7 / 10 Worth trying

Upside

Efficacy 3.6
Breadth 3.2
Evidence 3.6
Speed 2.0
Durability 2.6
Bioindividuality 2.5

Downside

Safety Risk 1.7
Side Effects 1.6
Cost 2.2
Effort 1.4
Opportunity Cost 1.8
Dependency 1.3
Reversibility 1.4

Best at:

Liver Detox 6.5
Gut Health 5.8
Metabolic Health 5.5
Blood Sugar 5.5

Taurine-conjugated bile acid, ER-stress chaperone. BioHarmony 6.7, worth trying.

Read full BioHarmony report →

Head-to-Head Verdict

Use Case	Winner	Rationale
Liver Detox	NAC (N-Acetylcysteine)	NAC 8.0 against TUDCA 6.5, and the row is more interesting than the numbers. NAC's liver evidence is the strongest single result in either report: Smilkstein 1988, 2,540 acetaminophen-overdose patients, 6.1% hepatotoxicity when started within 10 hours against 26.4% at 10 to 24 hours.TUDCA's liver evidence is bile-shaped: Pan 2013, a double-blind cirrhosis RCT, and Larghi 1997 in primary biliary cirrhosis. NAC takes the row on breadth and evidence tier. TUDCA is still the right molecule for a cholestatic problem.
Gut Health	TUDCA (Tauroursodeoxycholic Acid)	TUDCA 5.8 against NAC's 3.0, the clearest TUDCA win. This follows directly from mechanism rather than from a dedicated gut trial: TUDCA modulates the bile acid pool and bile flow through the farnesoid X receptor and bile salt export pump, and bile is what emulsifies fat. Sluggish digestion after fatty meals is a bile question. NAC has no route to it.
Blood Sugar	TUDCA (Tauroursodeoxycholic Acid)	TUDCA 5.5 against 3.0, on the single cleanest metabolic result either report holds for TUDCA. Kars 2010 gave obese men and women four weeks of TUDCA and measured roughly 30% better hepatic and skeletal-muscle insulin sensitivity, with no improvement in adipose tissue. It is a small study and the report scores it accordingly, at mid-scale rather than high.
Metabolic Health	TUDCA (Tauroursodeoxycholic Acid)	TUDCA 5.5 against NAC's 4.0, riding the same Kars 2010 insulin-sensitivity result plus the ER-stress chaperone mechanism. NAC's metabolic entry is thinner: Khoshbaten 2010 lowered ALT in 30 NAFLD patients against vitamin C, which the report itself calls small and preliminary.
Antioxidant	NAC (N-Acetylcysteine)	NAC 7.5 against TUDCA's 1.5, the widest gap on the board. NAC supplies the rate-limiting cysteine for glutathione synthesis and acts as a direct sulfhydryl antioxidant, which is what the entire category means. TUDCA is a bile acid and does not do this at all. If antioxidant capacity is the goal, there is no comparison to make.
Respiratory	NAC (N-Acetylcysteine)	NAC 7.5 against 1.5. PANTHEON (Zheng 2014) randomised 1,006 COPD patients to 600 mg twice daily and cut exacerbations from 1.49 to 1.16 per patient-year. Poole 2019 pooled 38 trials in 10,377 patients with a number-needed-to-treat of about 8 to keep one person exacerbation-free. Dose matters: BRONCUS at 600 mg once daily was null.
Substance Use	NAC (N-Acetylcysteine)	NAC 6.5 against 1.5, and this is where NAC's non-liver identity lives. Gray 2012 found 2.4 times the odds of a cannabis-negative urine in dependent adolescents. The honest counterweight sits in the same report: Gray 2017 in 302 adults was null, and LaRowe 2013 found benefit only in the already-abstinent subgroup. TUDCA has no mechanism here.
Mood	NAC (N-Acetylcysteine)	NAC 6.0 against 1.5, through glutamate modulation at the cystine-glutamate antiporter rather than through the liver. Fernandes 2016 pooled 5 trials in 574 people with a standardised mean difference of 0.37. The literature is split down the middle: Berk 2008 was strongly positive in bipolar depression and Berk 2019 in 181 people was null at 16 weeks.
Neuroprotection	Tie	TUDCA 5.2 against NAC 4.5, and the subrating is the wrong way to read this row. TUDCA's neuro reputation came from AMX0035, which combined taurursodiol with sodium phenylbutyrate, and the 664-participant PHOENIX Phase 3 trial missed its endpoints in 2024.Amylyx withdrew the product. Elia 2016 was a small positive add-on trial that has not been replicated. Neither supplement has earned a neuroprotection claim.

Cost Comparison

Intervention	Monthly Cost	Notes
TUDCA	$12 to $91	ESTIMATE, priced 2026-09-07, retail. Capsules run about $0.38 to $0.87 per 500 mg, so 500 mg a day is $12 to $26 a month and 1,750 mg a day is $40 to $91. The spread is the dose, not the brand. Supplement TUDCA is largely unregulated, so product identity and dose accuracy are a real cost you pay in verification rather than money.
NAC	$5 to $15	Extracted from the source report rather than estimated, priced 2026-09-07, retail. That band covers 600 to 1,800 mg a day, and the 600 to 1,200 mg general protocol sits in its lower half. Third-party-tested capsules are the normal route.
The difference	$7 to $76 a month, depending on TUDCA dose	At the doses most people actually take, NAC is roughly a third the price of low-dose TUDCA and a sixth the price of high-dose TUDCA. That is the case for trying NAC first when the target is general antioxidant or liver support and you have no specific bile complaint.Price stops mattering when the problem is cholestatic. No amount of cheap cysteine improves bile flow, so a $60 month of TUDCA that fixes fat digestion is better value than a $10 month of the wrong molecule.

When to Switch

Both take about the same time to judge, with a 12-week assessment window each, but they announce themselves differently. NAC's first noticeable change lands around 2 weeks and its report puts full effect out at 12 months, which is a long tail for a cheap capsule. TUDCA's first change is at about 4 weeks with full effect at 12. Neither is a same-week intervention.

Start with NAC in almost every case. It is a third to a sixth of the price, scores 8.0 against 6.7, and wins antioxidant, respiratory, mood, substance use and liver detox. Give it the full 12 weeks against a marker you chose in advance, whether that is ALT, exacerbation frequency or a symptom count.

Move to TUDCA when the complaint is specifically biliary: pale or greasy stools, discomfort after fatty meals, a cholestasis diagnosis, or an insulin-sensitivity question you want a second lever on.

Those are the rows TUDCA wins, and it wins them because it does something NAC's mechanism cannot reach. Get liver medication cleared first, because concurrent UDCA, cholestyramine or any other bile-acid drug is on TUDCA's contraindication list.

Running both is mechanistically clean. They share no target: NAC works through cysteine, glutathione and the cystine-glutamate antiporter, TUDCA through ER-stress chaperoning, the farnesoid X receptor and the bile salt export pump. No trial in either report combined them, so treat a stack as two separate experiments and change one thing at a time.

Who Should Pick What?

You want one cheap liver and antioxidant supplement with no specific complaint

NAC (N-Acetylcysteine)

Start here. 8.0 against 6.7 overall, $5 to $15 a month, antioxidant 7.5 against 1.5, and six decades of clinical use behind it. There is no argument for paying more for a narrower molecule before you have tried the broad cheap one.

Greasy or pale stools, discomfort after fatty meals, sluggish bile

TUDCA (Tauroursodeoxycholic Acid)

This is the specific case where the lower-scoring option is correct. Gut health 5.8 against 3.0, through bile acid pool modulation and bile flow. NAC has no mechanism that touches bile at all. Get a clinician to rule out obstruction first, because complete biliary obstruction is a contraindication.

COPD or chronic bronchitis with heavy mucus

NAC (N-Acetylcysteine)

Respiratory 7.5 against 1.5. PANTHEON (Zheng 2014) cut exacerbations 22% in 1,006 patients at 600 mg twice daily, and Poole 2019 pooled 38 trials with a number-needed-to-treat of about 8. Take the twice-daily dose: BRONCUS at 600 mg once daily was null. Avoid the inhaled form if you have reactive airways.

Insulin resistance you want a second lever on, alongside the basics

TUDCA (Tauroursodeoxycholic Acid)

Blood sugar 5.5 against 3.0 and metabolic health 5.5 against 4.0. Kars 2010 measured roughly 30% better hepatic and skeletal-muscle insulin sensitivity after four weeks in obese adults, though not in fat tissue. It is one small study, so treat it as a tracked experiment with before-and-after labs.

Exploring an adjunct for OCD, hair-pulling or addiction relapse

NAC (N-Acetylcysteine)

Substance use 6.5 against 1.5 and mood 6.0 against 1.5. Grant 2009 found 56% much or very much improved in trichotillomania against 16% on placebo, and Gray 2012 found 2.4 times the odds of a clean urine in adolescents. Do it with a clinician, and know that the pediatric replication (Bloch 2013) and the adult cannabis replication (Gray 2017) were both null.

Hoping to protect nerves or slow a neurodegenerative diagnosis

Tie

Neither, and TUDCA is the one to be careful about. Its neuro reputation came from AMX0035, a combination of taurursodiol and sodium phenylbutyrate, and PHOENIX failed in 664 participants in 2024 with the product withdrawn from market. That is not evidence for stand-alone TUDCA.

Already taking UDCA, cholestyramine or another liver medication

NAC (N-Acetylcysteine)

TUDCA is contraindicated without clearance, because you would be stacking bile-acid therapies. NAC has its own list to check: nitrates for additive hypotension, active peptic ulcer disease, anticoagulant or antiplatelet therapy for bleeding time, and known cysteine hypersensitivity.

Pregnant or breastfeeding

Tie

Neither without a clinician. Pregnancy is a listed contraindication on TUDCA and lactation needs guidance. NAC lists pregnancy and lactation as requiring medical supervision rather than an absolute stop, which is not the same as safe.

Hoping to prevent kidney injury before a contrast scan

Tie

Neither, and this one is settled rather than uncertain. ACT randomised 2,308 patients with identical 12.7% contrast-induced nephropathy rates, and PRESERVE randomised 4,993 with a 4.6% against 4.5% composite. Kidney subratings are 3.0 for NAC and 1.5 for TUDCA.

Research Highlights

Mechanism Difference
These two share no target, which is why the choice is a diagnosis rather than a preference. NAC supplies the rate-limiting cysteine for glutathione synthesis, acts as a direct sulfhydryl antioxidant, breaks mucin disulfide bonds and modulates glutamate through the cystine-glutamate antiporter.TUDCA is a taurine-conjugated bile acid working as a chemical chaperone against endoplasmic reticulum stress, hitting the farnesoid X receptor and the bile salt export pump, suppressing apoptotic signaling through CHOP and caspase-3, and improving bile flow. One raises antioxidant capacity. The other moves bile.
Liver Evidence
Both are called liver supplements and their liver evidence is about different injuries. NAC's is toxic and oxidative: Smilkstein 1988 in 2,540 acetaminophen-overdose patients cut hepatotoxicity to 6.1% when started within 10 hours against 26.4% at 10 to 24 hours, which is the basis of its FDA-approved antidote status.TUDCA's is cholestatic. Pan 2013 is a double-blind randomised trial in liver cirrhosis and Larghi 1997 a pilot crossover in primary biliary cirrhosis comparing UDCA with tauro-UDCA. Neither of those is a general detox result, and neither substitutes for treating ongoing liver injury.
Cost Comparison
NAC runs $5 to $15 a month for 600 to 1,800 mg a day, extracted from the source report at retail pricing. TUDCA runs $12 to $26 a month at 500 mg a day and $40 to $91 at 1,750 mg, an estimate from retail capsule pricing at roughly $0.38 to $0.87 per 500 mg. Both priced 2026-09-07.That makes NAC a third to a sixth of the price at comparable daily doses. It is the reason to try NAC first for anything general, and it is irrelevant the moment the problem is bile flow, because price does not make the wrong mechanism work.
Editorial Verdict
NAC scores 8.0 and TUDCA 6.7, and NAC wins six of the nine use cases both reports score, including liver detox at 8.0 against 6.5. It is cheaper, broader and better evidenced. For most people asking which liver supplement to buy, the answer is NAC.TUDCA wins gut health, blood sugar and metabolic health, and it wins them through bile acid signaling and ER-stress chaperoning that NAC cannot reach. Buy TUDCA when the complaint is biliary or the target is insulin sensitivity, not because it sounds more advanced.
Safety Comparison
Both are benign by supplement standards. TUDCA scores 1.7 on safety risk and 1.6 on side effects, NAC 1.6 and 1.8. The differences are in what they collide with rather than in what they do.TUDCA's contraindications are bile-shaped: pregnancy, lactation without guidance, complete biliary obstruction, and concurrent UDCA, cholestyramine or other liver medication without clearance.NAC's are pharmacological: nitrates for additive hypotension, active peptic ulcer disease, anticoagulant or antiplatelet therapy, cysteine hypersensitivity, and reactive airway disease for the inhaled mucolytic form only.
What Did Not Work
Both reports carry settled negatives worth knowing before you buy. NAC does not prevent contrast-induced kidney injury: ACT randomised 2,308 patients to identical 12.7% rates and PRESERVE randomised 4,993 to a 4.6% against 4.5% composite. NAC monotherapy for idiopathic pulmonary fibrosis was null in Martinez 2014.TUDCA's neuroprotection story collapsed in 2024. The 664-participant PHOENIX Phase 3 trial of AMX0035, a taurursodiol and sodium phenylbutyrate combination, missed its endpoints and Amylyx withdrew the product. Old optimism about the CENTAUR result is not evidence for stand-alone TUDCA.

Frequently Asked Questions

Which is better for the liver, TUDCA or NAC?: NAC on the score, 8.0 against 6.5 on liver detox, but the two treat different liver problems. NAC's evidence is toxic and oxidative injury, anchored by Smilkstein 1988 in 2,540 acetaminophen-overdose patients. TUDCA's is cholestatic, anchored by a cirrhosis RCT (Pan 2013) and a primary biliary cirrhosis crossover (Larghi 1997). Pick by which problem you have.
Should I take TUDCA if my bile is sluggish?: Yes, this is TUDCA's actual job. It modulates the bile acid pool and bile flow through the farnesoid X receptor and bile salt export pump, which is why its gut-health subrating is 5.8 against NAC's 3.0. Rule out complete biliary obstruction with a clinician first, and get clearance if you are already on UDCA, cholestyramine or another liver medication.
Is NAC worth taking if I have no liver problem?: Often yes, for reasons that are not about the liver. Its antioxidant subrating is 7.5, its respiratory 7.5 and its mood 6.0, and it costs $5 to $15 a month. Do not expect to feel it. For a healthy person it is quiet biochemical support rather than something you notice, which is a fair thing to buy at that price.
Can I take TUDCA and NAC together?: Mechanistically nothing conflicts. NAC works through cysteine, glutathione and the cystine-glutamate antiporter; TUDCA through ER-stress chaperoning, the farnesoid X receptor and bile flow. No trial in either report tested the combination, so run them as two separate experiments and add one at a time against a marker you chose in advance.
Does TUDCA protect nerves or help ALS?: The evidence went the wrong way. The excitement came from AMX0035, which combined taurursodiol with sodium phenylbutyrate, and the 664-participant PHOENIX Phase 3 trial missed its endpoints in 2024 with the product withdrawn from market. Elia 2016 was a small positive add-on trial that was never replicated. Do not buy TUDCA for this.
How long before either one works?: Both carry a 12-week assessment window. NAC's first noticeable change is around 2 weeks with its report putting full effect out at 12 months. TUDCA shows first change at about 4 weeks with full effect at 12. Pick a marker before you start, whether that is ALT, exacerbation count or how you handle a fatty meal, and judge at 12 weeks.
How much NAC should I take?: 600 to 1,200 mg a day for general antioxidant and glutathione support. If the target is COPD or chronic bronchitis, take 600 mg twice daily rather than once: PANTHEON used the twice-daily dose and cut exacerbations 22%, while BRONCUS at 600 mg once daily was null. Dose is the difference between those two results.
Is NAC safe to take every day?: For most people yes, with a specific list to check first. Its contraindications are nitrates because of additive hypotension, active peptic ulcer disease, anticoagulant or antiplatelet therapy because of bleeding-time effects, known cysteine hypersensitivity, and reactive airway disease for the inhaled mucolytic form only. Pregnancy and lactation need medical supervision.

Evidence Sources

Observational Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose (1988) 2,540 patients. Hepatotoxicity 6.1% when NAC started within 10 hours against 26.4% at 10 to 24 hours.
RCT Twice-daily N-acetylcysteine 600 mg for exacerbations of COPD (PANTHEON) (2014) 1,006 patients. Exacerbations 1.16 against 1.49 per patient-year, risk ratio 0.78.
RCT Effects of N-acetylcysteine on outcomes in COPD (BRONCUS) (2005) 523 patients at 600 mg once daily. Null for FEV1 decline and exacerbations. The dose-dependence signal.
Systematic review Mucolytic agents versus placebo for chronic bronchitis or COPD, Cochrane review (2019) 38 trials, 10,377 patients. Peto odds ratio 1.73 for staying exacerbation-free, number needed to treat about 8.
RCT N-acetylcysteine in the treatment of trichotillomania (2009) 50 participants. 56% much or very much improved against 16% on placebo.
RCT N-acetylcysteine in pediatric trichotillomania (2013) 39 participants. Null, 25% response against 21%. Contradicts the adult result.
RCT Double-blind RCT of N-acetylcysteine in cannabis-dependent adolescents (2012) 116 participants. 2.4 times the odds of a cannabis-negative urine.
RCT Randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults (2017) 302 adults. Null. The adolescent result did not replicate.
Meta-analysis N-acetylcysteine in depressive symptoms and functionality, meta-analysis (2016) 5 trials, 574 people. Pooled standardised mean difference 0.37.
RCT Adjunctive N-acetylcysteine in major depressive disorder and bipolar depression (2019) 181 participants. Null at 16 weeks, undercutting the 2008 bipolar signal.
RCT N-acetylcysteine improves liver function in NAFLD (2010) 30 patients. Significant ALT decrease against vitamin C. Small and preliminary.
RCT Acetylcysteine for prevention of renal outcomes in patients undergoing angiography (ACT) (2011) 2,308 patients. Contrast-induced nephropathy identical at 12.7% in both arms.
RCT Outcomes after angiography with sodium bicarbonate and acetylcysteine (PRESERVE) (2018) 4,993 patients. Composite 4.6% against 4.5%. The contrast-nephropathy question settled negative.
RCT Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis (2014) NAC monotherapy null. FVC change at 60 weeks -0.18 L against -0.19 L.
Review N-acetylcysteine in neurological disorders: mechanisms and therapeutic opportunities (2014) Cysteine donor for glutathione, direct antioxidant, glutamate modulation through system xc-.
Trial Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity (2010) Obese adults. Four weeks of TUDCA improved hepatic and skeletal-muscle insulin sensitivity but not adipose sensitivity.
RCT Efficacy and safety of tauroursodeoxycholic acid in liver cirrhosis, double-blind randomized controlled trial (2013) Hepatobiliary evidence in cirrhosis. Does not test general detox or wellness claims.
Trial Ursodeoxycholic and tauro-ursodeoxycholic acids for primary biliary cirrhosis, pilot crossover (1997) Crossover comparison of UDCA and tauro-UDCA. Makes the parent-versus-conjugate distinction explicit.
RCT Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis (2016) Small ALS add-on trial with a positive progression signal. Size and lack of replication keep confidence modest.
Press release Amylyx PHOENIX Phase 3 topline results (2024) 664 participants. The Phase 3 ALS trial of AMX0035 missed its primary and secondary endpoints.
Regulatory Amylyx RELYVRIO and ALBRIOZA market withdrawal (2024) April 2024 announcement removing the taurursodiol combination drug from market after the PHOENIX failure.
Review Tauroursodeoxycholate, bile acid with chaperoning activity: molecular and cellular effects (2019) Mechanistic review of ER-stress, apoptosis and inflammation pathways. Background biology rather than outcome evidence.

Glossary

Quick reference for the medical and technical terms used in this comparison.

TUDCA Tauroursodeoxycholic Acid: A taurine-conjugated bile acid. The supplement relative of UDCA, the approved cholestasis drug.
NAC N-Acetylcysteine: A stabilised form of the amino acid cysteine. It supplies the rate-limiting ingredient your body needs to build glutathione.
ER stress Endoplasmic Reticulum stress: What happens when a cell's protein-folding machinery is overloaded. TUDCA acts as a chemical chaperone that eases it.
FXR Farnesoid X Receptor: The bile acid sensor that regulates bile production and flow. One of TUDCA's targets, and nothing NAC touches.
system xc- Cystine-Glutamate Antiporter: The transporter that swaps cystine into cells for glutamate out. NAC's route to the mood and addiction effects.
ALT Alanine Aminotransferase: The liver enzyme most people track on a blood panel. The marker Khoshbaten 2010 moved with NAC in NAFLD patients.
COPD Chronic Obstructive Pulmonary Disease: Chronic airflow limitation with heavy mucus. NAC's strongest non-poisoning indication, at 600 mg twice daily.
Cholestasis Impaired bile flow: Bile not moving properly out of the liver. The specific problem TUDCA is built for and NAC cannot address.
AMX0035 Sodium phenylbutyrate plus taurursodiol: The combination ALS drug sold as Relyvrio. Its Phase 3 failure in 2024 is why TUDCA's neuroprotection claim collapsed.

Nick Urban Health Optimization Researcher & CHEK Holistic Lifestyle Coach Level 2

I like TUDCA for gut and bile health and rate it protective for the liver

Reviewed Sep 8, 2026 · next review Dec 7, 2026

Find which one fits your biology

Take the BioHarmony Quiz